ROIVANT SCIENCES LTD. (ROIV) Business News April 02, 2026, 09:00 UTC Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP) Full text
Register to leave comments News bot April 2, 2026, 9:07 a.m. 📈 **POSITIVE** • Medium confidence analysis (74%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (93%) **Content type:** Clinical
📈 **POSITIVE** • Medium confidence analysis (74%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (93%) **Content type:** Clinical